{"id":"NCT01682083","sponsor":"Novartis Pharmaceuticals","briefTitle":"Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).","officialTitle":"COMBI-AD: A Phase III Randomized Double Blind Study of Dabrafenib (GSK2118436) in COMBInation With Trametinib (GSK1120212) Versus Two Placebos in the ADjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-01-08","primaryCompletion":"2017-06-30","completion":"2023-07-31","firstPosted":"2012-09-10","resultsPosted":"2018-09-26","lastUpdate":"2023-08-30"},"enrollment":870,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Melanoma"],"interventions":[{"type":"DRUG","name":"Dabrafenib","otherNames":["GSK2118436"]},{"type":"DRUG","name":"Trametinib","otherNames":["GSK1120212"]},{"type":"DRUG","name":"Placebos","otherNames":[]}],"arms":[{"label":"Dabrafenib and trametinib","type":"EXPERIMENTAL"},{"label":"Dabrafenib and trametinib placebos","type":"PLACEBO_COMPARATOR"}],"summary":"This was a two-arm, randomized, double-blind Phase III study of dabrafenib in combination with trametinib versus two placebos in the adjuvant treatment of melanoma after surgical resection. Patients with completely resected, histologically confirmed, BRAF V600E/K mutation-positive, high-risk \\[Stage IIIa (lymph node metastasis \\>1 mm), IIIb or IIIc\\] cutaneous melanoma were screened for eligibility. Subjects were randomized to receive either dabrafenib (150 milligram (mg) twice daily \\[BID\\]) and trametinib (2 mg once daily \\[QD\\]) combination therapy or two placebos for 12 months.","primaryOutcome":{"measure":"Relapse-free Survival (RFS)","timeFrame":"Approximately 3.5 years","effectByArm":[{"arm":"Dabrafenib and Trametinib Combination Therapy","deltaMin":163,"sd":null},{"arm":"Dabrafenib and Trametinib Placebos","deltaMin":247,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":210,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Czechia","Denmark","France","Germany","Greece","Israel","Italy","Japan","Netherlands","New Zealand","Norway","Poland","Russia","Spain","Sweden","Switzerland","Taiwan","United Kingdom"]},"refs":{"pmids":["40250457","38899716","36653848","34225229","32877599","32007138","30928620","30343620","28891408"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":155,"n":435},"commonTop":["Fatigue","Pyrexia","Headache","Nausea","Diarrhoea"]}}